NCT04146051Phase 2Active not recruiting

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-01-05Actual

Enrollment · participants30Estimated

Source updated2026-08-14Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-08-14 · 2 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~31 Jul 2025~~

+ After

5 Jan 2026

Check registry source

Study details

Conditions studied

Myasthenia Gravis, Generalized

Treatments or interventions studied

Descartes-08Drug

Primary outcomes · main study measures

Read the study measures

measure: Proportion of patients with MG Composite improvement of ≥5 points.; description: In Part 3, the primary objective is to compare the effect of Descartes-08 versus placebo, as measured by the change in MGC score from baseline to Week 12. In Part 1, up to three ascending doses of Descartes-08 will be administered to each of 3 to 6 patients; the patients will be staggered at least 21 days apart and will complete a safety review between each dose. In Part 2, patients will receive up to 6 doses in three different schedules depending on the arm they were enrolled into and will be monitored for up to 1 year to assess the safety and tolerability of a repeated dosing schedule.; timeFrame: Day 0 to Day 85

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history